Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ.

Arch Gen Psychiatry. 1988 Sep;45(9):797-805.

PMID:
3415422
[PubMed - indexed for MEDLINE]
2.

Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.

Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG.

Arch Gen Psychiatry. 1997 May;54(5):453-63.

PMID:
9152099
[PubMed - indexed for MEDLINE]
3.

A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.

Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C.

Am J Psychiatry. 1994 Dec;151(12):1753-9.

PMID:
7977881
[PubMed - indexed for MEDLINE]
4.

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion.

Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ.

Arch Gen Psychiatry. 1986 Jul;43(7):633-42.

PMID:
2872870
[PubMed - indexed for MEDLINE]
5.

Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.

Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J.

Schizophr Res. 2002 Jan 1;53(1-2):25-30.

PMID:
11728835
[PubMed - indexed for MEDLINE]
6.

Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.

McClelland HA, Farquharson RG, Leyburn P, Furness JA, Schiff AA.

Arch Gen Psychiatry. 1976 Dec;33(12):1435-9.

PMID:
11760
[PubMed - indexed for MEDLINE]
7.

[Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].

Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K.

Pharmakopsychiatr Neuropsychopharmakol. 1980 May;13(3):117-29. German.

PMID:
7393998
[PubMed - indexed for MEDLINE]
8.

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.

Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR.

Arch Gen Psychiatry. 1987 Jun;44(6):518-21.

PMID:
3555385
[PubMed - indexed for MEDLINE]
9.

Costs and benefits of two doses of fluphenazine.

Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PR.

Arch Gen Psychiatry. 1984 Nov;41(11):1025-9.

PMID:
6437365
[PubMed - indexed for MEDLINE]
10.

Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view.

Kreisman D, Blumenthal R, Borenstein M, Woerner M, Kane J, Rifkin A, Reardon G.

Psychiatry. 1988 Feb;51(1):3-13.

PMID:
3368545
[PubMed - indexed for MEDLINE]
11.

Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.

Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT.

Am J Psychiatry. 1999 Mar;156(3):412-8.

PMID:
10080557
[PubMed - indexed for MEDLINE]
12.

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.

Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J.

Arch Gen Psychiatry. 1983 Aug;40(8):893-6.

PMID:
6347119
[PubMed - indexed for MEDLINE]
13.

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.

Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB.

Arch Gen Psychiatry. 1980 Jan;37(1):16-24.

PMID:
7352836
[PubMed - indexed for MEDLINE]
14.

Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.

Marder SR, Wirshing WC, Van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, Lebell M, Liberman RP.

Arch Gen Psychiatry. 1994 Apr;51(4):280-7.

PMID:
8161288
[PubMed - indexed for MEDLINE]
15.

Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.

Nuechterlein KH, Snyder KS, Dawson ME, Rappe S, Gitlin M, Fogelson D.

Psychopharmacol Bull. 1986;22(3):633-9. No abstract available.

PMID:
3797570
[PubMed - indexed for MEDLINE]
18.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
19.

The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.

Schooler NR, Levine J.

Pharmakopsychiatr Neuropsychopharmakol. 1976 Jul;9(4):159-69.

PMID:
790413
[PubMed - indexed for MEDLINE]
20.

The Nithsdale Schizophrenia Survey. VII. Does relatives' high expressed emotion predict relapse?

McCreadie RG, Phillips K.

Br J Psychiatry. 1988 Apr;152:477-81.

PMID:
3167397
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk